On 13 May, Celgene received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for Pomalyst (pomalidomide), one of its leading oncology brands, for the treatment of patients with human immunodeficiency virus (HIV) – positive or – negative Kaposi sarcoma.

Celgene’s Pomalyst

This marks the first label expansion opportunity for Pomalyst in a new indication following its initial FDA approval in 2013 for relapsed/refractory multiple myeloma (MM) patients who progressed on Revlimid (lenalidomide) and a proteasome inhibitor. With the BTD, the company is expected to market Pomalyst for Kaposi sarcoma as early as in the first half of 2020.

In the face of increasing scrutiny over the value creation potential of BMS’ Celgene acquisition, the positioning of Pomalyst outside of the highly competitive MM market is a strategic move that will augment the revenues of Pomalyst and help to further assure BMS shareholders that the buyout will pay off not only through new drug launches but also via positioning of Celgene’s currently marketed therapies in new therapeutic indications.

Unlike in MM, where Pomalyst is being used in later treatment lines and facing growing competition from novel therapies, there are no FDA-approved targeted therapies for HIV-positive Kaposi sarcoma patients who are refractory to chemotherapy, an area of unmet need that Pomalyst can address in the absence of any competition. The label expansion opens up yet another avenue of growth for BMS in addition to the five new brands expected to launch from the Celgene pipeline through 2020.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.